Modella AI and AstraZeneca link for cancer clinical development
The partnership will give AstraZeneca access to Modella AI's multi-modal foundation models.
The agreement will enable the use of Modella AI's latest models, with rich feature extraction from different types of data, to speed up clinical development across AstraZeneca's worldwide oncology portfolio.
AstraZeneca oncology research and development (R&D) chief AI and data scientist Jorge Reis-Filho stated: 'At AstraZeneca, AI is integrated across every aspect of clinical development.
'Through the use of foundation models, combined with our unique datasets and AI expertise, we are confident in our strategy to accelerate development and increase the probabilities of success in our oncology clinical trials.'
AstraZeneca will use Modella AI's platform for cancer research R&D capabilities to improve biomarker discovery and clinical development while enhancing patient outcomes.
By integrating these advanced foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods with increased speed.
Modella AI CEO Jill Stefanelli stated: 'Foundation models are transforming precision medicine. They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents.
'Our state-of-the-art multimodal foundation models provide powerful features from different data types for downstream tasks. When integrated with AstraZeneca's research engine, they will have the potential to accelerate data-driven development and enable the development of new AI agents that can automate complex R&D workflows.'
In June 2025, the US Food and Drug Administration (FDA) approved AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that exhibits mutations in the epidermal growth factor receptor.
"Modella AI and AstraZeneca link for cancer clinical development" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nvidia, Microsoft, Palantir Lead Wedbush's Top Tech Bets on $2T AI Boom
July 4 - Wedbush Securities projects a more than 10% gain for major tech stocks in the second half of 2025, driven by a surge in enterprise and government AI spending. The top five picks are Nvidia (NASDAQ:NVDA), Meta Platforms (META), Microsoft (NASDAQ:MSFT), Palantir (NASDAQ:PLTR) and Tesla (NASDAQ:TSLA). Analysts estimate roughly $2 trillion will flow into AI initiatives over the next three years, unlocking new use cases and boosting demand for both software and semiconductors. Warning! GuruFocus has detected 4 Warning Signs with NVDA. Wedbush points to recent strength in tech amid tariff and geopolitical headwinds as a prelude to further market outperformance. They highlight the rollout of large language models and the true adoption of generative AI in corporate settings as key catalysts for renewed rallies. With enterprise consumption set to accelerate, we believe software and chip leaders are well positioned to lead this AI Revolution' through 2026, the note added. Investors will watch second?half earnings and AI deployment updates closely to see if these leaders can sustain the momentum. This article first appeared on GuruFocus. Sign in to access your portfolio
New York Times
an hour ago
- New York Times
Trump Signs Signature Policy Bill at Independence Day Event
President Trump signed a sweeping domestic policy bill into law on Friday, cementing a major political victory that was timed to take place during Independence Day celebrations. Accompanied by a flyover of B2 bombers, the same aircraft used in the recent bombing of Iran, Mr. Trump touted the massive tax cuts included in the bill and downplayed the unpopularity of the legislation in polls and the potential impact of spending cuts. 'The largest spending cut, and yet, you won't even notice it,' Mr. Trump said while standing with the first lady, Melania Trump, on the balcony of the White House. 'The people are happy, they're happy,' he added. Mr. Trump highlighted a list of measures included in the enormous bill he believes are popular, singling out, for example, the expansion of the Child Tax Credit and a reduction in estate taxes. He spoke only in generalities about deep spending cuts to programs like Medicaid and food assistance. The legislation carries significant risks for the Republican Party. The law is estimated to cause the national debt to balloon by trillions of dollars, and the cuts to Medicaid could leave 11.8 million more people without health insurance by 2034, breaking Mr. Trump's promise earlier this year that he would not 'touch' the entitlement. Democrats in the opposition roundly denounced the bill as a move to slash critical government programs to pay for tax breaks for the wealthiest Americans. They have made it clear that they will attack Mr. Trump and Republican lawmakers for pushing through those and other measures that polls have shown are deeply unpopular. Want all of The Times? Subscribe.
Health Line
an hour ago
- Health Line
Treatment Options for Brain Cancer
Key takeaways Surgery, radiation therapy, and chemotherapy are common treatments for brain cancer, and they can be used alone or in combination. The specific approach depends on the cancer's characteristics and location. Targeted and electric field therapies are additional options for managing brain cancer. Clinical trials, like those researching immunotherapy, also offer promising new treatments that could improve the outlook for people with this condition. A brain tumor happens when cells in your brain begin to grow and divide out of control. While some brain tumors are benign (noncancerous), others are malignant (cancerous). There are a few different treatments that may be used for brain cancer, either alone or together. And clinical trials are currently testing new treatments for brain cancer that can help to improve your outlook. Keep reading to learn more about each treatment, how it's used, and the side effects associated with it. Can you survive brain cancer? It's possible to survive brain cancer. But survival can vary greatly based on many factors, such as the type of brain cancer that you have and your age. Surgery for brain cancer Surgery is a part of treatment for many brain cancers. During surgery, a neurosurgeon will try to remove as much of the tumor as possible without affecting the function of your brain. Surgery is often done by craniotomy. This is where a small opening is made in your skull, allowing for access to your brain. You may be under general or local anesthesia during surgery. While operating, a neurosurgeon can use various techniques to help them safely remove your tumor without damaging the surrounding tissue. These can include: Using surgery in combination with other brain cancer treatments like radiation therapy (RT) may be able to eliminate smaller, less aggressive cancers. But this can be more challenging for cancers that are larger or more aggressive. Surgery can also be used for other purposes. These include inserting a shunt or drain to reduce intracranial pressure or placing an Ommaya reservoir to help deliver chemotherapy (chemo). Side effects of surgery for brain cancer Some of the possible side effects of surgery for brain cancer may include: a reaction to the anesthetic infections bleeding swelling of the brain seizures loss of brain function Radiation therapy for brain cancer RT uses high-energy radiation to destroy cancer cells. It's often given for brain cancer using a radiation source located outside of your body. This is called external beam RT. Radiation has the potential to damage healthy brain tissue, so several methods have been developed to help lower this risk. An example of one is conformational RT, which makes a 3D image of your tumor and shapes the radiation to fit to it. You may receive RT after surgery to help kill any remaining cancer cells. RT may also be one of the main treatment options if your cancer can't be operated on. This may be the case if your cancer is: very extensive located deep within your brain found at or around an area that's vital for brain function Side effects of radiation therapy for brain cancer Some of the potential side effects of RT for brain cancer are: fatigue nausea or vomiting headache hair loss cognitive changes, which can include issues with memory, difficulties with concentration, or changes in personality increased risk of a second cancer Chemotherapy for brain cancer Chemo uses drugs that disrupt the ability of cancer cells to grow and divide. It can be used along with other treatment types, such as surgery or RT, or alone when other treatments haven't been effective. While many chemo drugs are given directly into your bloodstream or taken orally, this isn't always possible with brain cancer. The reason is that many chemo drugs can't cross the blood-brain barrier. As such, some chemo may be given directly into your cerebrospinal fluid. Other types of chemo may also be given as a wafer that's placed in your brain during surgery. A few examples of chemo drugs used for brain cancer, either alone or in combination, are: carmustine lomustine procarbazine temozolomide vincristine Side effects of chemotherapy for brain cancer The possible side effects of chemo include: nausea or vomiting diarrhea mouth sores loss of appetite hair loss low blood counts, which can cause: anemia an increased risk of infections easy bleeding Targeted therapy for brain cancer Targeted therapy uses drugs that target specific markers on or in cancer cells. Currently, there are only a handful of targeted therapy drugs used for brain cancer. Bevacizumab (Avastin) inhibits a protein that promotes the growth of blood vessels around tumors. It's given by an intravenous (IV) line and may be used to treat glioblastoma. Everolimus (Afinitor) blocks the activity of a protein involved in cell growth and division. It's taken as a pill and is used for some types of astrocytomas. Side effects of targeted therapy for brain cancer Specific side effects can vary based off of the targeted therapy drug used. But some of the more general side effects of targeted therapy drugs may include: fatigue loss of appetite nausea diarrhea mouth sores headache an increased risk of infections Alternating electric field therapy for brain cancer Alternating electric field therapy exposes a tumor to electric fields that affect its ability to grow. This type of therapy involves the use of a wearable device called the Optune system that generates those electric fields. The Optune system is used for people who recently received a diagnosis of glioblastoma or those who have recurrent glioblastoma. Side effects of alternating electric field therapy for brain cancer Some of the side effects that you may have while using alternating electric field therapy include: skin irritation where the device and its electrodes are placed on your scalp headache seizures low blood counts and digestive side effects when used with chemo Clinical trials for brain cancer Clinical trials evaluate potentially new or improved ways to treat a disease or disorder. They're essential for testing the safety and effectiveness of new treatments before they're made more widely available. One type of treatment that's being heavily researched for brain cancer is immunotherapy. This is a type of cancer treatment that helps your immune system respond to cancer. It's already used for many other cancer types. For some people with brain cancer, receiving treatment through a clinical trial may be recommended. This is particularly true if you have a cancer that: is rare or very aggressive has a limited number of approved treatment options hasn't responded to conventional treatments has come back after treatment If you're interested in a clinical trial for brain cancer, talk with your medical care team. They can recommend clinical trials you may qualify for. You can also find clinical trials through the website of the National Brain Tumor Society or by searching What's the outlook for a person with brain cancer? The outlook for people with brain cancer depends on many factors. These include: the type of brain cancer you have the grade of the cancer, which estimates how quickly the tumor may grow where the tumor is in your brain how large the tumor is whether or not the tumor can be removed using surgery and, if so, how much of the tumor can be removed the presence of certain genetic changes in the tumor cells your age and overall health For example, the 5-year relative survival rate for adults ages 20–44 years old with diffuse astrocytoma, a slow-growing cancer, is 73%. In contrast, the 5-year relative survival rate is 22% in the same age group for glioblastoma, an aggressive cancer. If you've recently received a diagnosis of brain cancer, your medical care team will consider all of the factors above to give you a better idea of your individual outlook. Relative survival rate vs. survival rate A relative survival rate suggests how long someone with a condition may live after receiving a diagnosis compared with someone without the condition of the same race, sex, and age over a specific time. This is different from overall survival rate, which is a percentage of people still alive for a specific time after receiving a diagnosis of a condition.
